Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Articles

Catch up on coverage from the second day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee. 

Day 2 Recap: Maui Derm NP+PA Fall 2024

During his session at Maui Derm NP+PA Fall, Hawkes emphasized the need for careful patient communication and shared his excitement for remibrutinib.

Jason Hawkes, MD: Urticaria Characteristics, Patient Concerns, and Therapies

Allie Karas is the vice president of content for the Health Care Specialty Group division of MJH Life Sciences. She attended Rider University and earned a degree in journalism before pursing a masters in magazine writing from New York University. Prior to making a switch to health care news in 2018, Allie spent 6 years in New York City working in political journalism. She enjoys spending time with her husband and 3 kids, cooking, working out, and her dog Bo. Follow her on Twitter at 

This Maui Derm NP+PA Fall session discusses the latest advancements in hidradenitis suppurativa treatment, the evolving therapeutic landscape, and the critical need for timely diagnosis and aggressive care.

Raj Chovatiya, MD, PhD: Hidradenitis Suppurativa Is the ‘Definition of Unmet Need’

Researchers analyzed APPs treatment and perceptions on AD in studies focusing on patient satisfaction and patients with skin of color.

Importance of APPs in Treating and Understanding AD

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Twitter

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

For years, teenagers have been told to avoid certain foods to reduce acne. A review article examines the evidence.

 Does diet really play a role in acne?

An extensive literature review looks at the dermatoses that are connected to video game play.

Video games and skin ailments 

The US Food and Drug Administration (FDA) has approved Eli Lilly and Company's lebrikizumab-lbkz (Ebglyss)

 for children and adults aged 12 years and older with moderate to severe atopic dermatitis (AD).

The IL-13 inhibitor is intended for adults and pediatric patients whose AD has not yet been controlled through the use of topical therapies. Children 12 years of age and older must weigh at least 88 pounds (40 kg).

The approval is supported by positive data stemming from the ADvocate 1, ADvocate 2, and ADhere studies.

"Patients still struggle to control their moderate-to-severe atopic dermatitis with currently available therapies. Many experience poor long-term disease control, and severe itch can significantly impact their daily lives," said Jonathan Silverberg, MD, PhD, MPH, professor of dermatology at George Washington University School of Medicine and Health Sciences in Washington, DC, in a news release.

 Silverberg is also the first author of the manuscript for the clinical trials related to lebrikizumab. 

The studies, involving over 1,000 patients with moderate to severe eczema who didn't respond to topical treatments, primarily measured clear or almost clear skin at the 16 week mark. 

In an average of the ADvocate 1 and ADvocate 2 studies, 38% of those using lebrikizumab achieved clear skin at 16 weeks, compared to 12% with placebo, and 10% saw results as early as 4 weeks. Of those who achieved clear skin, 77% maintained it for a year with monthly doses, and 48% maintained it even after switching to placebo.

For itch relief, 43% of lebrikizumab users experienced relief at 16 weeks, versus 12% with placebo, with 5% feeling relief as early as 2 weeks. Among those with itch relief at week 16, 85% continued to feel relief after a year on monthly maintenance, and 66% maintained relief after switching to placebo.

"Today's FDA approval of Ebglyss is a big win for patients, as we now have a new first-line biologic treatment option for moderate-to-severe disease when topical prescriptions aren't enough," he said.

Kristin Belleson, president and CEO of the 

, weighed in on the approval's significance for patients.

"Eczema can affect people of all skin tones, ethnicities, genders and ages. Nearly 16.5 million adults in the US have eczema, with 6.6 million experiencing moderate-to-severe symptoms like itchiness, dry and scaly skin, discoloration and rashes, which can lead to more scratching that may cause skin to crack and bleed," Belleson said. "The approval of Ebglyss provides hope and promise for the eczema community and those still seeking lasting relief from disruptive symptoms."

Lebrikizumab was approved by the European Commission in 2023,

 Japan in January 2024, and Canada in June 2024.

Lebrikizumab will be available as a 250 mg/2 mL injection and may be used with or without topical corticosteroids. Lilly anticipates the drug will become available in the US in a matter of weeks. 

FDA approves Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children 12 years and older with moderate-to-severe atopic dermatitis. News release. Lilly. September 13, 2024. Accessed September 13, 2024. 

https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-ebglysstm-lebrikizumab-lbkz-adults-and#:~:text=INDIANAPOLIS%20%2C%20Sept.%2013%2C%202024,88%20pounds%20(40%20kg)%20with

Almirall. Almirall receives European Commission approval of Ebglyss (lebrikizumab) for moderate-to-severe atopic dermatitis. News release. November 17, 2023. Accessed September 13, 2024. 

https://www.almirall.com/newsroom/news/almirall-receives-european-commission-approval-of-ebglyss-lebrikizumab-for-moderate-to-severe-atopic-dermatitis

Health Canada authorizes Lilly's Ebglyss (lebrikizumab) for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older. News release. Cision; Eli Lilly Canada Inc. June 25, 2024. Accessed September 13, 2024. 

https://www.newswire.ca/news-releases/health-canada-authorizes-lilly-s-ebglyss-tm-lebrikizumab-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-adults-and-adolescents-12-years-and-older-833722064.html

Ebglyss is now approved for children and adults aged 12 years and older.

News 

clinical

FDA Approves Lebrikizumab-lbkz for Moderate to Severe Atopic Dermatitis

"Atopic dermatitis (AD) remains a challenging condition to manage effectively, and despite advances in treatment, there is a persistent issue of therapeutic inertia in the field. This inertia, characterized by the failure to escalate treatment when patients do not meet their therapeutic targets, continues to undermine patient outcomes. The 

 has highlighted this issue in the real-world, showing that many patients with moderate-to-severe AD remain undertreated, leading to inadequate disease control and reduced quality of life," wrote Christopher Bunick, MD, PhD, associate professor of dermatology and translational biomedicine at Yale University School of Medicine in New Haven, Connecticut, and 

recent review of new atopic dermatitis treatment targets.

The chronic physical symptoms of AD such as itchy and painful skin are often associated with affecting patients’ quality of sleep, sexual and social interactions, and work productivity. Due to the mental and physical effects of AD combined with dissatisfaction with current treatment regimens, more effective therapies are needed. 

Answer the poll below to learn more about recently published atopic dermatitis treatment recommendations.

The TARGET-DERM registry longitudinal study highlighted the continued trend of the failure to escalate atopic dermatitis treatments when patients do not meet their therapeutic targets.

POLL: When Do You Escalate AD Treatment if Treatment Targets are Not Achieved?

Each year, dermatology clinicians have a plethora of conferences to attend across the US, and even internationally. Although you may not be able to attend them all, there is no shortage of new data presented at each conference. Specific meetings geared towards dermatology advanced practice providers are growing in both quantity and size. Just last month, the inaugural Inflammatory Disease Summit in Las Vegas, Nevada, kicked off an exciting first year. 

Out of the meetings listed below, which one did you enjoy the most? Or, email us at 

As we get ready to plan for a busy 2024, check back for additional meeting opportunities!

Fall Clinical Dermatology Conference for PAs & NPs

Society of Dermatology Nurse Practitioners

Society of Dermatology Physician Assistants

Dermatology Education Foundation (DEF) - DERM2023 NP/PA CME Conference 

DEF Biologic & Small Molecule NP/PA CME Bootcamp

Masterclasses in Psoriatic Disease Plus for APP+

Click here to answer this week's NP & PA poll. Out of the meetings listed below, which one did you enjoy the most?

Polls 

POLL: Which of the Following 2023 NP & PA Conferences Has Been Your Favorite?

Mr George Johnson is a 68-year-old retired preschool teacher who presents a persistent pruritic rash, and a history of recurrent cardiovascular events, including a myocardial infarction 2.5 years ago. He reports a history of atopic dermatitis that has been relatively well controlled until recently; the itching has become more irritating, and he reports sleep disturbances as a result.

Physical examination reveals tractable facial erythema and lateral eyebrow shedding (Hertoghe’s sign). Lichenification is evident on extended sides of the elbows and knees. The patient's skin appears generally dry.

Patient and caregiver education highlighting proper bathing practices (eg, avoid hot baths, reduce frequency) and regular application of moisturizers.

Low dose of calcineurin inhibitors ointment mixed with an emollient. 

First-generation antihistamines before bedtime, with cautious monitoring. 

A biologic (eg, dupilumab or tralokinumab). 

What would you suggest or prescribe for these AD symptoms in a 68-year-old man? Test your knowledge and take a look at new data on AD in older patients.

DermIQ 

The Gray Area: A Challenging Case of AD in an Older Patient

Hyperhidrosis is not rare. According to the 

, approximately 385 million people worldwide live with hyperhidrosis.

In fact, they note that the amount of people living with chronic, excessive sweating is even higher than the amount of people living with other dermatologic conditions like psoriasis.

Just how common is hyperhidrosis in real-world comparisons?

The prevalence of hyperhidrosis is much higher in younger populations than in the general population, with 8.8% of individuals between the ages of 18 to 39 years old living with the condition. 

When comparing these statistics to everyday, common occurrences like hair color, the number of people with hyperhidrosis is greater than the 1% of individuals with natural red hair and 2% of individuals with natural blond hair. 

Despite how common hyperhidrosis is, it is estimated that 27% of those with the condition never receive a diagnosis.

 wants to hear from you. What percentage of the global population is estimated to have hyperhidrosis?

 to share your hyperhidrosis insights or research.

Albert. Fact check: Hyperhidrosis - International Hyperhidrosis Society: Official site. Home - International Hyperhidrosis Society. October 24, 1970. Accessed November 16, 2023. 

https://www.sweathelp.org/home/news-blog/542-fact-check-hyperhidrosis.html

Click here to answer this week's poll for Hyperhidrosis Awareness Month.

POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?

Combination therapy (eg, topical agents + procedures)

Lilit Garibyan, MD, PhD, and Sara Moradi Tuchayi, MD, MPH, of 

, topical agents such as kojic acid, cysteamine, and rucinol should be avoided among patients who are pregnant. 

Share your recommended melasma treatment pearls or additional methods not mentioned above with us by emailing 

Click here to answer this week's melasma poll. 

Jon Matthew Farber, MD

Articles

Latest Updated Articles